心梗发作后速降胆固醇有益身体
http://www.100md.com
2000年11月16日
NEW ORLEANS (Reuters Health) - Giving heart attack patients high doses of cholesterol-lowering drugs as quickly as possible may reduce the risk of heart problems in the 4 months after the attack, researchers reported at the American Heart Association (news - web sites) meeting here.
The study included more than 3,000 patients with a non-Q-wave myocardial infarction, a type of heart attack that makes up about half of the 1.5 million heart attacks that occur every year in the US. Half the patients were given the cholesterol-lowering drug atorvastatin (Lipitor) within 4 days of their heart attack and half were given an inactive placebo drug.
, 百拇医药
At 16 weeks, about 17% of those in the placebo group had another heart attack, chest pains requiring hospitalization or died. In comparison, less than 15% of those taking atorvastatin had such problems--a statistically significant difference.
Overall, the LDL (''bad'') cholesterol dropped from 124 mg/dL to 72 mg/dL in those taking atorvastatin, but actually increased slightly in those taking a placebo, according to Dr. Anders G. Olsson of the University of Linkoping, Sweden, and Dr. Gregory G. Schwartz of the Denver Veterans Affairs Medical Center in Colorado.
, 百拇医药
The cholesterol-lowering drug was particularly helpful in reducing the risk of stroke and unstable angina--chest pain unrelated to exercise or exertion, Schwartz reported.
And the high dose of the drug appeared to be safe and well-tolerated. About 2.5% of patients had problems with liver function, but the problem resolved when they discontinued the drug.
``Patients with a threatened or mild heart attack benefit (from aggressive atorvastatin therapy),'' Schwartz said. ``It should be initiated in the hospital and should be considered irrespective of cholesterol levels,'' he added.
, http://www.100md.com
``Whether another dose or another statin would have equivalent effects, we can only speculate. We tried one drug at one dose and it worked,'' Schwartz said.
In a second, similar trial, researchers gave 550 heart attack patients fluvastatin (Lescol) or a placebo within 8 days of having a heart attack. At 6 weeks and 12 months, major health problems occurred in 17% of patients on fluvastatin and 17% of those taking a placebo.
Dr. Ad J. van Boven and Anho Liem of the University Hospital Groningen, the Netherlands, noted that a few patients benefited from fluvastatin, particularly those with episodes lasting for more than 44 minutes. At one year, 2.5% of patients taking fluvastatin had died, as did 4% of placebo patients, but the results were not statistically significant, the researchers report., http://www.100md.com
The study included more than 3,000 patients with a non-Q-wave myocardial infarction, a type of heart attack that makes up about half of the 1.5 million heart attacks that occur every year in the US. Half the patients were given the cholesterol-lowering drug atorvastatin (Lipitor) within 4 days of their heart attack and half were given an inactive placebo drug.
, 百拇医药
At 16 weeks, about 17% of those in the placebo group had another heart attack, chest pains requiring hospitalization or died. In comparison, less than 15% of those taking atorvastatin had such problems--a statistically significant difference.
Overall, the LDL (''bad'') cholesterol dropped from 124 mg/dL to 72 mg/dL in those taking atorvastatin, but actually increased slightly in those taking a placebo, according to Dr. Anders G. Olsson of the University of Linkoping, Sweden, and Dr. Gregory G. Schwartz of the Denver Veterans Affairs Medical Center in Colorado.
, 百拇医药
The cholesterol-lowering drug was particularly helpful in reducing the risk of stroke and unstable angina--chest pain unrelated to exercise or exertion, Schwartz reported.
And the high dose of the drug appeared to be safe and well-tolerated. About 2.5% of patients had problems with liver function, but the problem resolved when they discontinued the drug.
``Patients with a threatened or mild heart attack benefit (from aggressive atorvastatin therapy),'' Schwartz said. ``It should be initiated in the hospital and should be considered irrespective of cholesterol levels,'' he added.
, http://www.100md.com
``Whether another dose or another statin would have equivalent effects, we can only speculate. We tried one drug at one dose and it worked,'' Schwartz said.
In a second, similar trial, researchers gave 550 heart attack patients fluvastatin (Lescol) or a placebo within 8 days of having a heart attack. At 6 weeks and 12 months, major health problems occurred in 17% of patients on fluvastatin and 17% of those taking a placebo.
Dr. Ad J. van Boven and Anho Liem of the University Hospital Groningen, the Netherlands, noted that a few patients benefited from fluvastatin, particularly those with episodes lasting for more than 44 minutes. At one year, 2.5% of patients taking fluvastatin had died, as did 4% of placebo patients, but the results were not statistically significant, the researchers report., http://www.100md.com